Study S001187

Early Proctologic Effects of GLP-1 Receptor Agonist Therapy in Morbidly Obese Patients: A Prospective Cohort Study With Baseline and 3-Month Proctologic Assessment

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07668765
Acronym: GLP-PROCT
Study type: OBSERVATIONAL
Status: NOT_YET_RECRUITING
Enrollment: 100
Start: 2026-08
Primary completion: 2027-04
Lead sponsor: Gazi University
Conditions: Morbid Obesity; Anorectal Diseases; Drug-Related Side Effects and Adverse Reactions; Constipation; Diarrhea
Interventions: DRUG:GLP-1 receptor agonist therapy
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Incidence of newly developed proctologic disease [3 months]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0017776	GLP-1 receptor agonists and delayed gastric emptying: implications for invasive cardiac interventions and surgery. Shankar A, Cardiovascular endocrinology & metabolism	2025	Narrative review	PMID 39649679 DOI	registry reference RESULT:39649679
R0023506	Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. Wadden TA, JAMA	2021	Randomized trial	PMID 33625476 DOI	registry reference RESULT:33625476
R0021242	Adverse Effects of GLP-1 Receptor Agonists. Filippatos TD, The review of diabetic studies : RDS	2014	Nonrandomized study	PMID 26177483 DOI	registry reference BACKGROUND:26177483